Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Day One Biopharmaceuticals Stock Up 3.4 %
NASDAQ:DAWN opened at $14.13 on Friday. Day One Biopharmaceuticals, Inc. has a 52 week low of $9.67 and a 52 week high of $18.07. The stock’s 50-day moving average price is $14.35 and its 200-day moving average price is $14.64. The stock has a market capitalization of $1.24 billion, a PE ratio of -5.63 and a beta of -1.51.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $0.90 million. Sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -1.68 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Day One Biopharmaceuticals
Analysts Set New Price Targets
Several research firms have recently commented on DAWN. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, July 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.71.
View Our Latest Stock Report on DAWN
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Recommended Stories
- Five stocks we like better than Day One Biopharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- What Investors Need to Know to Beat the Market
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.